Prestige Biologics Co Ltd
334970
Company Profile
Business description
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
Contact
197, Osongsaengmyeong 1-ro
Osong-eup, Heungdeok-gu
Chungcheongbuk-do
Cheongju-si28161
KORT: +82 432321552
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
250
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors too optimistic about ASX growth story
Investors have gotten ahead of themselves with shares trading at a 94% premium to fair value.
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,106.30 | 44.00 | -0.48% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,458.61 | 483.52 | 1.10% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 25,329.76 | 360.08 | 1.44% |
| NASDAQ | 21,681.90 | 296.50 | 1.39% |
| Nikkei 225 | 43,301.07 | 582.90 | 1.36% |
| NZX 50 Index | 12,833.16 | 73.48 | 0.58% |
| S&P 500 | 6,445.76 | 72.31 | 1.13% |
| S&P/ASX 200 | 8,830.90 | 49.90 | -0.56% |
| SSE Composite Index | 3,675.85 | 9.93 | 0.27% |